Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038388 · ClinicalTrials.gov registry record · Phase 1
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01038388 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 30 participants.
The verdict
NCT01038388, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the clinical effectiveness and side effects of the vorinostat, bortezomib, lenalidomide, and dexamethasone investigational combination.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Bortezomib
- DRUG Vorinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-01-15 |
| Est. Completion | 2021-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01038388
The ClinicalTrials.gov registry entry for NCT01038388 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01038388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01038388 about?
NCT01038388 is a clinical study titled "A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma". The purpose of the study is to evaluate the clinical effectiveness and side effects of the vorinostat, bortezomib, lenalidomide, and dexamethasone investigational combination.
What is the current status of trial NCT01038388?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-01-15. Estimated completion is 2021-08-05.
What interventions are being tested in trial NCT01038388?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Bortezomib (DRUG), Vorinostat (DRUG).
Who is sponsoring clinical trial NCT01038388?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.